ESMO Highlights | Professor WeiYu’s Commentary on Advances in Neoadjuvant Therapy and Bladder Preservation in Bladder Cancer
Bladder cancer is a common tumor in the urinary system, with muscle-invasive bladder cancer (MIBC) accounting for approximately 20% of all bladder cancers. Nearly half of non-muscle-invasive bladder cancer (NMIBC) patients may relapse into MIBC. Currently, various explorations in neoadjuvant therapy, including chemotherapy, immunotherapy, and their combination, have been conducted. The recent ESMO conference revealed several advancements in research. Professor Wei Yu from Peking University First Hospital shares the latest developments in neoadjuvant therapy and bladder preservation for bladder cancer.